Lemuteporfin
- Generic Name
- Lemuteporfin
- Drug Type
- Small Molecule
- Chemical Formula
- C44H48N4O10
- CAS Number
- 215808-49-4
- Unique Ingredient Identifier
- EZ109VJ012
- Background
Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
- Indication
Intended for the treatment of benign prostatic hyperplasia and prostrate disorders.
Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Dermira, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT01490736
- Locations
- 🇨🇦
Innovaderm Research, Inc, Montreal, Quebec, Canada
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
- Conditions
- Prostatic Hyperplasia
- First Posted Date
- 2005-06-30
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00116571
- Locations
- 🇺🇸
Devine Tidewater Urology, Virginia Beach, Virginia, United States
🇨🇦Can-Med Clinical Research Inc, Victoria, British Columbia, Canada
🇺🇸AccuMed Research Associates, Garden City, New York, United States
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- QLT Inc.
- Registration Number
- NCT00077012
- Locations
- 🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
🇺🇸Raymond Fay, MD, Inc, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.